Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. This is how Gilead Sciences prepared for the moment.

Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.

Emergency approval of the antiviral drug remdesivir is the first good news of this pandemic. This is how Gilead Sciences prepared for the moment.Hosts: Carol Massar and Jason Kelly. Producer: Doni Holloway.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more. Watch us LIVE on YouTube: http://bit.ly/3vTiACF.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more. Watch us LIVE on YouTube: <a href="http://bit.ly/3vTiACF">http://bit.ly/3vTiACF</a>.

Carol Massar and Tim Stenovec bring together the latest news from the world of business and finance and the interesting stories of global technology, politics, economics and more by harnessing the power of Bloomberg Businessweek reporters and editors.

Bloomberg Businessweek

All Eyes on Gilead

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ced0cc6a-96bd-4967-b2cd-ae2b007313f8/transcript

Advertisement